How do we manage t(11;14) plasma cell disorders with venetoclax?
Rajshekhar ChakrabortyDivaya BhutaniSuzanne LentzschPublished in: British journal of haematology (2022)
The oral BCL-2 inhibitor venetoclax has demonstrated promising efficacy in patients with t(11;14) plasma cell disorders, both as a single-agent and in combination. However, there was an increased mortality signal in the randomized BELLINI trial that was primarily driven by non-t(11;14) patients. Based on current evidence, venetoclax is included as an option for relapsed/refractory t(11;14) plasma cell dyscrasias in NCCN guidelines and is being widely used in clinical practice. In this review, we aim to critically appraise the current literature and perform case-based illustration of our approach to management of t(11;14) plasma cell disorders with venetoclax.
Keyphrases
- single cell
- cell therapy
- clinical practice
- systematic review
- end stage renal disease
- clinical trial
- acute lymphoblastic leukemia
- phase iii
- chronic kidney disease
- chronic lymphocytic leukemia
- ejection fraction
- stem cells
- cardiovascular disease
- open label
- study protocol
- acute myeloid leukemia
- double blind
- cardiovascular events
- prognostic factors
- diffuse large b cell lymphoma
- risk factors